CUPERTINO, Calif., Feb. 25, 2021 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX) today announced that it will report
its fourth quarter and year ended December
31, 2020 financial results and host a conference call after
the market close on Thursday, March 4,
2021.
Thursday, March 4 @
4:30pm Eastern Time /
1:30 p.m. Pacific Time
Toll Free:
|
877-407-0784
|
International:
|
201-689-8560
|
Conference
ID:
|
13715968
|
Webcast:
|
http://public.viavid.com/index.php?id=143367
|
About DURECT Corporation
DURECT is a biopharmaceutical company committed to
transforming the treatment of acute organ injury and chronic liver
diseases by advancing novel and potentially lifesaving therapies
based on its endogenous epigenetic regulator program. DUR-928, the
company's lead drug candidate, is in clinical development for the
potential treatment of alcohol-associated hepatitis (AH) for which
FDA has granted a Fast Track Designation; COVID-19 and
non-alcoholic steatohepatitis (NASH) are also being
explored. In addition, POSIMIR® (bupivacaine solution)
for infiltration use, a non-opioid analgesic utilizing the
innovative SABER® platform technology, is now FDA-approved.
Full prescribing information about POSIMIR, including the Boxed
Warning, can be found at www.posimir.com. For more information
about DURECT, please visit www.durect.com and follow us on Twitter
https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statement
The statements in this press release regarding the potential for
DUR-928 to treat patients with AH, NASH, COVID-19, or other acute
organ injury and chronic liver diseases, plans for clinical
development of DUR-928, and the commercial potential of POSIMIR are
forward-looking statements involving risks and uncertainties that
can cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
include, but are not limited to, the risks that the clinical trial
of DUR-928 in AH takes longer to conduct than anticipated due to
COVID-19 or other factors, or that the clinical trial of DUR-928 in
COVID-19 patients is delayed or stopped because of changes to the
standard of care, the availability of alternative therapies,
protocol changes or lack of available patients, the risk that
clinical trials of DUR-928 do not confirm the results from earlier
clinical or pre-clinical trials, or do not demonstrate the safety
or efficacy or the life saving potential of DUR-928 in a
statistically significant manner, risks that we or a third-party
licensee may not commercialize POSIMIR successfully, if at all, and
risks related to our ability to obtain capital to fund operations
and expenses. Further information regarding these and other risks
is included in DURECT's Form 10-Q filed on November 3, 2020 under the heading "Risk
Factors."
NOTE: POSIMIR® and SABER® are trademarks
of DURECT Corporation. Other referenced trademarks belong to
their respective owners. DUR-928 is an investigational drug
candidate under development and has not been approved for
commercialization by the U.S. Food and Drug Administration or other
health authorities for any indication. Full prescribing information
for POSIMIR, including its Boxed Warning, can be found at
www.posimir.com.
View original
content:http://www.prnewswire.com/news-releases/durect-corporation-to-announce-2020-financial-results-and-provide-business-update-on-march-4-301236050.html
SOURCE DURECT Corporation